celecoxib; tramadol hydrochloride · Kowa Pharms · NDA 213426
Seglentis
Earliest generic entry, as listed
3 Jun 2031
No marketed reference-listed strength; date taken from all listed strengths.
Blocked by patent: US 8846744.
Listed patents · 7 unexpired
| Patent | Claims | Expires |
|---|---|---|
| US 8846744 | product | 3 Jun 2031 |
| US 10238668 | substance, product, use U-3244 | 19 Apr 2030 |
| US 10245276 | substance, product | 19 Apr 2030 |
| US 10548909 | use U-3244 | 19 Apr 2030 |
| US 11478488 | use U-3244 | 19 Apr 2030 |
| US 8598152 | substance, product | 19 Apr 2030 |
| US 9012440 | substance, product | 19 Apr 2030 |
Exclusivities · 0 unexpired
No unexpired exclusivities listed.
Paragraph IV certifications · 0
No Paragraph IV certification listed by FDA for this drug.
The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.
Event history
No events yet. The first ingestion only records products entering their 12-month window; changes appear from the next Orange Book update.
Products covered · 1
| NDA · product | Form | Strength | Listed expiry |
|---|---|---|---|
| 213426 · 001 · RLD · discontinued | tablet, oral | 56MG;44MG | 3 Jun 2031 |